Introduction
Epidemiological studies have suggested that different populations have a higher prevalence of specific autoimmune diseases. [1] [2] [3] [4] [5] [6] [7] [8] For example, rheumatoid arthritis has a higher prevalence in certain Amerindian populations [1] [2] [3] and type 1 diabetes a higher prevalence in European populations. With regard to admixed populations, investigations have demonstrated that type 1 diabetes in Mexican Americans is associated with the European HLA contribution. 8 For systemic lupus erythematosus (SLE), previous studies have reported an increased prevalence of this disease in African Americans. 6, 7 More convincingly a more recent study correlated SLE incidence with West African contribution in individual subjects in an Afro-Caribbean population. 5 Although other studies suggest that Amerindian ancestry may also contribute increased risk for SLE, 9, 10 no formal study has demonstrated this risk or examined the relationship between susceptibility and ancestry in individual subjects from a European/Amerindian admixed population. Importantly, studies have suggested more severe disease and poorer outcomes in Hispanic compared to European American patients in Texas. 9 In the current study, we took advantage of genotyping studies being performed in Argentine cases and controls to examine whether Amerindian ancestry was associated with SLE susceptibility and particular clinical and serologic subtypes. Recently, our group has examined the admixture characteristics in Argentina. 11 These studies using ancestry informative markers (AIMs) indicated that overall, the Argentine population has approximately 80% European and 20% Amerindian contribution. Further, it confirmed previous studies 12 that there is a minimal West African admixture with the vast majority of the subjects having less than 3% contribution from this continent. Importantly, for the current study, regional differences in Amerindian contributions were observed.
To examine admixture characteristics in Argentine SLE patients and controls, we utilized selected genotypes from a 100 K single-nucleotide polymorphism array (Affymetrix, Santa Clara, CA, USA) that was used as an initial screen for association testing. Specific AIMs were selected from those overlapping with an Illumina 300 K panel (Illumina, San Diego, CA, USA) that we had previously used in genotyping two disparate Amerindian groups, Pima and Mayan Amerindians. 13 These AIMs had (1) large frequency differences (445%) between European populations and both the Amerindian populations (2) For this study, both patients (255 subjects) and controls (256 subjects) were recruited from seven sites within Argentina (listed in Figure 1 and Supplementary Table  2 ). The control subjects studied were all healthy, and all subjects were not first-degree relatives of each other based on self-reporting. All DNA and blood samples were obtained according to protocols and informed consent procedures approved by institutional review boards and were labeled with an anonymous code number. Each of the SLE cases met American College of Rheumatology SLE criterion. 17, 18 Subjects with incomplete demographic information or o95% complete genotypes were excluded. A summary of the clinical characteristics of 248 cases included in the final analyses is provided in Supplementary Table 2 and included 105 patients that met ACR criteria for renal disease. Controls were collected from the same sites and were friends of the cases. The controls were matched for both gender and age (within 5 years of age). This control set (friends of cases) was chosen to minimize the effects of nongenetic factors. For the final set analyzed, the cases and controls were closely matched for age and gender: case mean/median case age ¼ 45/44; control mean/median control age ¼ 45/43; case gender, 94.0% female; control gender, 92.2% female; the number of cases and controls at most recruitment sites was similar.
Population genetic structure was examined in a total of 254 SLE cases and 251 controls using STRUCTURE. For initial analyses, we included genotypes from three continental groups (European, Mayan Amerindian and African) and Mexican American subjects as another comparative group. As expected, the log likelihood results strongly favored three groups (K ¼ 3) using the F model, in which no prior ancestry information was used in the analysis. The results (Figure 1a ), similar to our previous studies in Argentina, 11 showed that the continental contribution was predominantly European and Amerindian. Only a minimal contribution of West African ancestry was observed (1.9% overall), with only 28 participants with 45% West African ancestry. To further examine the effect of European/Amerindian ancestry, we removed six cases and five controls that were 41 s.d. above mean West African ancestry. After removal of the outliers, the mean West African admixture in both cases and controls was less than 1.3%. The subsequent analyses, using the remaining 248 cases and 246 controls, showed that the STRUCTURE analyses were consistent with the assumption of two population groups. The mean 90% Bayesian confidence interval for individual ancestry assignment was 12% (e.g. 30.1% CI 23.9-36.5%).
The population structure results showed a higher Amerindian contribution in the cases compared to controls: mean/median Amerindian contribution cases 25.9/26.5%; mean/median Amerindian contribution controls 19.1/13.3%. The distribution of cases and controls showed a shift in relative Amerindian contribution in the cases (Figure 1b) . This finding was also consistent at the majority of collection sites further suggesting that the difference was not due to geographic differences within Argentina (Figure 1c) . The relationships were then more formally examined using univariate and multivariate logistic regression, in which the effects of Amerindian ancestry on SLE susceptibility were examined using age, gender and site of collection as covariates. Here, the Bayesian estimates of individual admixture were used in classical logistic regression models fitted in SAS9.1 (SAS Institute, Inc., Cary, NC, USA). The results (Table 1) showed a strong effect of Amerindian ancestry with an odds ratio of 7.94 (95% confidence interval (CI) 2.9-22.2). Similar results were also obtained when an alternative computational program, ADMIXMAP 19 was utilized: (odds ratio Amerindian ancestry ¼ 7.8, 95% CI ¼ 2.7-23.3).
In addition, we examined whether Amerindian ancestry was also associated with particular SLE phenotypes ( Table 2) . Although none of the results were significant, there were trends for renal disease, early age of onset and presence of anti-SSA that suggested that Amerindian ancestry may also be associated with particular clinical or serologic subtypes. Both the Amerindian admixture association with the prevalence of kidney disease and earlier age of onset are consistent with studies comparing Hispanic and Caucasian SLE patients in Texas and in Latin America. 10, 22, 23 These studies found that the Hispanic group, largely composed of Amerindian/ European admixed individuals, had a much higher frequency of kidney disease and was associated with an earlier age of onset.
In summary, our data demonstrate that Amerindian ancestry within Argentina is strongly associated with increased SLE susceptibility. From our available data, we cannot, at present, directly distinguish if this increase in susceptibility is independent of socioeconomic or other non-genetic factors. However, our strategy of selecting Figure 1 Population genetic structure analysis of Argentine systemic lupus erythematosus (SLE) cases and controls. Population admixture proportions were determined using the Bayesian clustering algorithms implemented in the program STRUCTURE v2.1. 16 Each analysis was performed without any prior population assignment and was performed at least three times with similar results using 10 000 replicates and 5000 burn-in cycles under the admixture model. We used the 'infer a' option with a separate a estimated for each population (where a is the Dirichlet parameter for degree of admixture). Runs were performed under the l ¼ 1 option, where l parameterizes the allele frequency prior and is based on the Dirichlet distribution of allele frequencies. control subjects who were friends of the cases should minimize the possibility that such factors can explain the current results. The current study also does not distinguish whether correlation is due to increased effect or number of Amerindian susceptibility genes or a combination or even synergism of European and Amerindian susceptibility genes. Studies in NZB/NZW mice, in which it is the combination of genes from different genetic backgrounds that predisposes to autoimmunity, suggest that the latter possibility cannot be dismissed. Indeed, while certain Amerindian populations appear to have an increased incidence of SLE, the majority of Amerindian populations have a frequency of SLE similar to that of European and European American populations. 24 Future studies in other populations, for example Mexican population groups, in which the overall Amerindian admixture percentage is much higher may allow further exploration of this relationship.
It is also worth noting that the analysis of specific known or suspected SLE susceptibility genes in this admixed population may be fruitful. In this regard, specific studies of the IRF5 risk haplotype have suggested that the stronger association of IRF5 in Mexican SLE is due to a higher frequency of risk haplotypes in Mexican Amerindians. 25 Thus, European/Amerindian admixed populations like those with West African admixture may be particularly useful in further genetic studies to identify particular gene variants that predispose to SLE. It is also worth noting that many Hispanic populations also have West African admixture and the combined effects of European, Amerindian and African ancestry is currently unknown. The effect of Amerindian ancestry demonstrated by the current study suggests that application of admixture mapping 26 as well as whole genome association studies in Amerindian/European admixed populations will be of substantial future interest. The individual Bayesian ancestry estimate (STRUCTURE output) was used in logistic regression to determine the ancestry odds ratio for systemic lupus erythematosus. Analyses were performed using SAS 9.1. were assessed as positive. Antibodies against the extractable nuclear antigens nRNP, Sm antigen, SSA(Ro60), SSA(Ro52), SSB, Scl-70 and Jo-1 were determined by an immunoblot method from Euroimmun (Lü beck, Germany). Results were reported as positive (positive or weakly positive) or negative in relation to reference sera. Combined anti-SSA refers to individuals scored positive for either anti-Ro60 or anti-Ro52. Anti-cardiolipin antibodies were measured by an ELISA, Varelisa from Pharmacia (Uppsala, Sweden). The values were reported in GPLU (IgG PhosphoLipid Units) per ml and sera with concentrations of 441 GPLU ml À1 were assessed as positive. Antibodies against C1q were measured by ELISA, essentially as described. 21 The collagenlike portion of C1q was used as antigen in the assay. Bound IgG was detected by enzyme-conjugated F(ab 0 ) 2 antibodies to IgG. Results are reported in arbitrary units (AU) with the upper limit of the reference interval being 16 AU ml
À1
. The reference interval corresponds to the 95% percentile in healthy blood donors.
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